We are excited to announce that Golden Helix will be participating in AMP 2023, a pivotal event that brings together experts and innovators in the field of molecular pathology. This year, we are proud to present a session that is at the forefront of precision medicine: “Comprehensive Genomic Profiling in Oncology: Apply the AMP Guidelines for TSO-500 Variant Analysis and Clinical Reporting.”

The landscape of molecular oncology is rapidly evolving, and with it, the demand for robust and dynamic tools capable of interpreting complex genomic markers is growing. Our session will focus on the capabilities of VarSeq software, which is meticulously engineered to meet these demands. VarSeq is tailored for laboratories conducting Comprehensive Genomic Profiling (CGP) and is aligned with the AMP guidelines for variant scoring and reporting.

During the session, we will explore the application of VarSeq in a clinical setting, emphasizing its ability to automate and scale up to meet the demands of large multi-omics panels such as the Illumina TruSight Oncology 500 (TSO-500) kit. We will take a deep dive into the evaluation and clinical reporting of genomic signatures like Microsatellite Instability (MSI), Tumor Mutation Burden (TMB), PD-L1 expression, and Homologous Recombination Deficiency (HRD), all within the framework of AMP guidelines.

The talk will also cover the automated oncogenicity scoring capabilities of VarSeq. With large panels, automated annotation and filtering are essential to detect somatic variants of interest efficiently. VarSeq’s automated scoring algorithm applies cancer-specific criteria to all imported variants, streamlining the filtering and prioritization process.

Furthermore, we will introduce the updated Golden Helix CancerKB, which includes report-ready interpretations that provide drug response, diagnostic, and prognostic information. The CancerKB has been enhanced to include multi-biomarker interpretations, approved therapies at the tumor-specific level, gene-level cancer hallmarks, and clinically relevant negative findings.

We invite you to join us at AMP 2023 to explore the cutting-edge developments in VarSeq that are setting new benchmarks for genomic data interpretation and reporting in the realm of molecular oncology. For more details on our session times and topics, please visit our event page: AMP 2023 – Golden Helix Events.

• Thursday, November 16:
  • 11:55 – Automation of Clinical NGS Testing with VarSeq and VSWarehouse
  • 2:20 – AMP Guideline Based Somatic NGS Workflow with VarSeq and VSClinical
  • 2:55 – Carrier Status and Hereditary Cancer Testing Analysis in VarSeq
  • 3:40 – Golden Helix CancerKB: Report Ready Curations to Support the AMP Guidelines
  • 4:30 – NGS Copy Number Variant Calling and Interpretation: A Complete Clinical Workflow
  • 6:10 – TSO500 and Tackling the Complexity of Comprehensive Genomic Profiling
• Friday, November 17:
  • 9:10 – TSO500 and Tackling the Complexity of Comprehensive Genomic Profiling
  • 9:45 – NGS Copy Number Variant Calling and Interpretation: A Complete Clinical Workflow
  • 11:55 – Golden Helix CancerKB: Report Ready Curations to Support the AMP Guidelines
  • 12:40 – 1:10 Innovation Spotlight (Stage 2): Comprehensive Genomic Profiling in Oncology: Apply the AMP Guidelines for TSO-500 Variant Analysis and Clinical Reporting
  • 2:55 – Carrier Status and Hereditary Cancer Testing Analysis in VarSeq
  • 3:15 – AMP Guideline Based Somatic NGS Workflow with VarSeq and VSClinical
  • 3:45 – Automation of Clinical NGS Testing with VarSeq and VSWarehouse
• Saturday, November 18:
  • 9:10 – AMP Guideline Based Somatic NGS Workflow with VarSeq and VSClinical
  • 9:35 – Golden Helix CancerKB: Report Ready Curations to Support the AMP Guidelines
  • 10:00 – TSO500 and Tackling the Complexity of Comprehensive Genomic Profiling
  • 11:55 – Automation of Clinical NGS Testing with VarSeq and VSWarehouse
  • 12:20 – Carrier Status and Hereditary Cancer Testing Analysis in VarSeq
  • 12:50 – NGS Copy Number Variant Calling and Interpretation: A Complete Clinical Workflow

Don’t miss this opportunity to stay at the forefront of genomic data analysis and clinical reporting. We look forward to seeing you there!